Tech Company Financing Transactions

GenomeDx Biosciences Funding Round

GenomeDx Biosciences, operating out of Vancouver BC, secured investment capital from Merck Global Health Innovation Fund, Aeris Capital AG and Baird Capital.

Transaction Overview

Company Name
GenomeDx Biosciences
Announced On
9/30/2013
Transaction Type
Venture Equity
Amount
Unknown
Round
Series B
Investors

Merck Global Health Innovation Fund (Lead Investor)

Aeris Capital AG (George Rehm)

Baird Capital (Michael Liang)

CD Ventures

Proceeds Purpose
This additional capital will be used to further expand the commercialization of the Decipher prostate cancer test, the first and only commercially available genomic test that predicts the risk of developing metastatic prostate cancer independently of PSA and other conventional risk assessment tools.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1152 Mainland St. 430
Vancouver BC, V6B 4X2
Canada
Phone
(888) 792-1601
Website
www.genomedx.com
Email Address
[email protected]
Overview
GenomeDx is a genomic information company developing solutions for prostate cancer treatment and the management of other urologic cancers.
Profile
GenomeDx Biosciences LinkedIn Company Profile
Social Media
GenomeDx Biosciences Company Twitter Account
Company News
GenomeDx Biosciences News
Facebook
GenomeDx Biosciences on Facebook
YouTube
GenomeDx Biosciences on YouTube

Management Team

Title
Name
Email & Social
Chief Medical Officer
Douglas Dolginow
  Douglas Dolginow LinkedIn Profile  Douglas Dolginow Twitter Account  Douglas Dolginow News  Douglas Dolginow on Facebook
President
Elai Davicioni
  Elai Davicioni LinkedIn Profile  Elai Davicioni Twitter Account  Elai Davicioni News  Elai Davicioni on Facebook
VP - General Counsel
Adam Chinnock
  Adam Chinnock LinkedIn Profile  Adam Chinnock Twitter Account  Adam Chinnock News  Adam Chinnock on Facebook

 

 

Browse more venture capital transactions:

Prev: 9/30/2013: Riskpulse venture capital transaction
Next: 9/30/2013: eXacly venture capital transaction

 

Share this article

 

About Our VC Transactions Data

We do our best to report on all VC transactions involving tech companies. VC investment data records on this site come from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.